Previous 10 | Next 10 |
2023-04-12 09:58:06 ET Century Therapeutics ( NASDAQ: IPSC ) said its Chief Executive Officer Lalo Flores had stepped down as Chief Executive Officer and as a member of the Board of Directors to pursue other opportunities. The company said it had appointed Chief Tech...
– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer – – Michael C. Diem, M.D., promoted to Chief Financial Officer ȁ...
2023-03-16 07:33:38 ET Century Therapeutics press release ( NASDAQ: IPSC ): FY GAAP EPS of -$2.27 beats by $0.05 . Revenue of $5.2M misses by $1.76M . For further details see: Century Therapeutics GAAP EPS of -$2.27 beats by $0.05, revenue of $5.2M misses...
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected into 2026 – PHILADELPHIA, March 16, 2023 (GLOBE NEWSWIRE) -- Century The...
PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company’s i...
– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch – – ELiPSE-1 trial to test multi-dosing strategy for CAR iNK e...
Listen on the go! Subscribe to Wall Street Breakfast on Apple Podcasts and Spotify Nonfarm payrolls report to provide insight into inflation , Fed policy. Raytheon (RTX) exploring $1B sale of actuation business - report. ChatGPT creator ...
Century Therapeutics ( NASDAQ: IPSC ) will lay off 25% of its workforce and prioritize certain programs in its pipeline in a move to extend its cash runway into 2026 . None of the cancer immunology-focused biotech's candidates are in the clinic. It is partnered with Bristol-Myers ...
- Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma - - Employee headcount reduced by approximately 25 percent, extending cash runway into 2026 - - Phase 1 stud...
PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at...
News, Short Squeeze, Breakout and More Instantly...
Century Therapeutics Inc. Company Name:
IPSC Stock Symbol:
NASDAQ Market:
Century Therapeutics Inc. Website:
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA m...
In vitro data showcases CNTY-101’s ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE) Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD30...
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoim...